FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan

      TD Cowen Initiates Coverage on MapLight Therapeutics with Buy Rating

      MapLight Therapeutics, Inc. (NASDAQ:MPLT) has received a Buy rating from TD Cowen analyst Joseph Thome, who initiated coverage on the small-cap stock on April 7. Thome highlighted the company's promising pipeline of treatments aimed at addressing central nervous system and neuropsychiatric conditions.

      The analyst believes that MapLight is undervalued, particularly in relation to its potential treatments for schizophrenia. This assessment positions the company as a compelling investment opportunity in the biotech sector, especially for those looking to invest in innovative therapies.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud